- Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1
- SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant
- Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far, the company has explored MDMA, LSD, DMT, mescaline, 2C-B, and psilocybin mushrooms (https://ibn.fm/iIiQu).
These efforts have offered more effective alternatives to individuals dealing with treatment-resistant depression, anxiety, or post-traumatic stress disorder (“PTSD”). As it currently stands, over 63% of Americans who have used prescription medications to treat depression, anxiety, or PTSD, have reported that while the medication helped, they still underwent residual feelings of their conditions.
In addition, 83% of those who have experienced these conditions before have noted that they are open to exploring alternative treatments that are more effective than prescription medications.
In what marked a significant move for the company, Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings and the largest ketamine therapy provider in the United States, announced the expansion of its treatment options to include SPRAVATO(R) nasal spray beginning April 1 (https://ibn.fm/0r6nf).
SPRAVATO is the first FDA-approved ekestamine nasal spray for adults, made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions.
SPRAVATO received FDA approval for the treatment of TRD back in 2019 following an efficacy evaluation in three short-term (four-week) clinical tests, along with one longer-term maintenance-of-effect trial. The nasal spray would be used in conjunction with an oral antidepressant and would only be available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy (“REMS”) (https://ibn.fm/uyb48).
While making the announcement, Kevin Nicholson, the Chief Executive Officer (“CEO”) of KWC and the Chief Operating Officer (“COO”) of Delic, noted that the introduction of SPRAVATO underscores KWC’s commitment to providing clinically-backed, accessible, and affordable treatments to patients nationwide. He further pointed out that the company’s dedication to offering the highest quality service available, coupled with its vast network of ketamine clinics, allows it to serve more patients than any other ketamine therapy provider.
“Ketamine Wellness Centers strives to be our patients’ strongest advocate by providing effective and affordable mental health treatment, and SPRAVATO is the next step in maintaining that standard,” Mr. Nicholson noted.
Patients who might be interested in this treatment option will undergo KWC’s thorough intake and screening process to ensure they are suitable candidates and would gain the most benefit from the treatment. In addition, KWC’s clinical protocols provide that SPRAVATO treatments are administered in precisely the proper care and patient safety settings.
“Our team rigorously studied SPRAVATO’s clinical efficacy before offering the treatment to our wider patient community and expanding our care options,” noted Mr. Nicholson.
“We are confident that adding this treatment to our mental wellness centers will greatly benefit our patients,” he added.
Since Delic completed the acquisition of KWC in November 2021, it has been on an aggressive expansion plan, growing the number of locations to 13, up from 10, with plans to open more locations in the coming months. So far, these facilities serve communities across nine states in the United States and have provided over 70,000 treatments to clinically eligible patients, ranging from young adults to seniors (https://ibn.fm/2gL1y).
The addition of SPRAVATO to KWC’s list of offerings guarantees more options for its patients. In addition, it allows both KWC and Delic to provide effective and affordable mental health treatment to patients across the country.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
